SAN ANTONIO--(BUSINESS WIRE)--Dec 12, 2019-- ... BIOTECHNOLOGY HEALTH CONSUMER PHARMACEUTICAL SCIENCE ONCOLOGY.
News
- Silverback Therapeutics Announces Preclinical Data at 2019 San Antonio Breast Cancer ...
- Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 ...
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of ... HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio ...
- Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid ...
Phase 1 clinical findings were featured within a spotlighted presentation at the annual 2019 San Antonio Breast Cancer Symposium (SABCS) by ...
- The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix ...
The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls ... Puma Biotechnology Inc (NASDAQ: PBYI) presented at the San Antonio ...
- Updated APHINITY Supports Benefit of Dual HER2 Blockade
SAN ANTONIO, Texas — An updated analysis of the APHINITY trial .... G1 Therapeutics, Huya Bioscience International, Immunomedics, Eli Lilly, The ...